CCR Inhibitor

Ccr3 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Ccr3 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

HGS004 is a humanized IgG4 monoclonal antibody inhibitor targeting CCR5. HGS004 has potent antivival activity against a diverse panel of CCR5-tropic HIV-1 and durg (such as Maraviroc (HY-13004))-resistant strains. HGS004 can be used for HIV-1 infections research.

Ccr4 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Ccr4 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

CB-0821 is a high affinity CCR5 inhibitor with a K_i of 0.04 nM. CB-0821 binds efficiently to the hydrophobic pocket of the CCR5 protein, to inhibit the interactions between viral protein and CCR5, thereby inhibiting viral entry. CB-0821 has the potential for anti-HIV research.

PROTAC IRAK4 degrader-14 is an orally active IRAK4 PROTAC degrader with a DC₅₀ of 2.4 nM. PROTAC IRAK4 degrader-14 inhibits proinflammatory responses in multiple cell types including T cells, monocytes and keratinocytes. PROTAC IRAK4 degrader-14 is applicable to research related to psoriasis.

HFB101110 is a human-derived inhibitor and Treg depleter that specifically targets CCR8. It does not bind to the homologous CCR4 receptor and is mainly used in research on solid tumors, renal cell carcinoma and colorectal cancer. HFB101110 blocks hCCL1 binding by interacting with the N-terminal extracellular domain of hCCR8, thereby inhibiting hCCL1-induced calcium influx, chemotaxis and downstream signaling pathways. Meanwhile, HFB101110 can mediate ADCC effects to specifically deplete CCR8-positive cells, including intratumoral Tregs. HFB101110 exhibits favorable anti-tumor activity and pharmacokinetic properties.

Catenarin, an anthraquinone compound, inhibits CCR5- and CXCR4-mediated chemotaxis. Catenarin reduces the phosphorylation of mitogen-activated protein kinases (p38 and JNK) and their upstream kinases (MKK6 and MKK7), and calcium mobilization. Catenarin shows anti-inflammatory effect and suppresses leukocyte migration in the diabetes. Catenarin exhibits significant inhibitory effects against Gram-positive bacteria. Catenarin prevents type 1 diabetes (T1D) in nonobese diabetic mice^[1][2].

HZ-1127 is a thymic stromal lymphopoietin (TSLP) inhibitor. HZ-1127 selectively binds to TSLP, blocks receptor complex interaction, inhibits STAT5 activation, downstream inflammatory signaling, and TSLP-induced CCL17 and CCL22 secretion. HZ-1127 can be used for the research of allergic diseases and cancer.

Histamine glutarimide (XC8) is an orally active anti-asthma agent. Histamine glutarimide blocks the maturation of chemokines (CCL2, CCL7, CCL8, CCL13) and inhibits the migration of eosinophils and the degranulation of mast cells. In asthma models induced by carrageenan and rat ovalbumin, Histamine glutarimide can reduce airway resistance and the count of eosinophils in bronchoalveolar lavage fluid. Histamine glutarimide can be used in asthma research.

CCR9 Human Pre-designed siRNA Set A contains three designed siRNAs for CCR9 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

Ophiobolin C inhibits CCR5 binding to the envelop protein gp120 and CD4, which is responsible for mediating the entry of HIV-1 into cells. Ophiobolin C is also cytotoxic to chronic lymphocytic leukemia cells.

Reftinirsen inapertide is a CNOT3 inhibitor. CNOT3 is a non-catalytic subunit of the CCR4-NOT complex, serving as a direct transcriptional repressor and penetrance modifier of PRPF31. Reftinirsen inapertide can be used for the research of retinal dystrophies associated with prpf31 mutations.

IBS007125 is a c-Maf inhibitor. IBS007125 does not alter the protein level or post-translational modification of c-Maf. IBS007125 inhibits some target genes of c-Maf (such as ITGB7 and CCR1). IBS007125 exerts anticancer effects on multiple myeloma expressing c-Maf. IBS007125 can be used for the research of multiple myeloma.

Emapticap pegol scramble negative control, an oligonucleotide aptamer, is the negative control of Emapticap pegol (HY-148100).

VLST-002 is a humanized antibody expressed in CHO cells, targeting CCL5/RANTES. VLST-002 has a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for VLST-002 can refer to Human IgG1 kappa, Isotype Control (HY-P99001).

Anti-Mouse CCR3/CD193 Antibody (6S2-19-4) is a rat-derived IgG2b λ type antibody inhibitor, targeting to mouse CCR3/CD193. Anti-Mouse CCR3/CD193 Antibody (6S2-19-4) can deplete eosinophils. Anti-Mouse CCR3/CD193 Antibody (6S2-19-4) can be used for the researches of cancer, infection, inflammation and immunology, such as lymphoma, ileitis and strongyloides stercoralis infection.

Enzelkitug is a humanized immunoglobulin G1-κ monoclonal antibody targeting the human C-C motif chemokine receptor 8 (CCR8). Enzelkitug is promising for research of various solid tumors and hematological malignancies.

CCR5/CXCR3-IN-1 (compound 1) is a CXCR3 and CCR5 inhibitor. CCR5/CXCR3-IN-1 inhibits chemotaxis of CXCR3 and CCR5-expressing transformed cells, and does not inhibits the chemotaxis of transfected cells expressing CXCR4. CCR5/CXCR3-IN-1 can be used for the study of chronic arthritic rheumatism.

7,4'-Dihydroxyflavone (7,4'-DHF) is a flavonoid, which can be isolated from Glycyrrhiza uralensis. 7,4'-Dihydroxyflavone is eotaxin/CCL11 inhibitor and CBR1 inhibitor (IC50=0.28 μM). 7,4'-Dihydroxyflavone has the ability to consistently suppress eotaxin production and prevent dexamethasone (Dex)‐paradoxical adverse effects on eotaxin production. 7,4'-Dihydroxyflavone (7,4'-DHF) inhibits MUC5AC gene expression, mucus production and secretion via regulation of NF-κB, STAT6 and HDAC2.7,4'-Dihydroxyflavone (7,4'-DHF) decreases phorbol 12-myristate 13-acetate (PMA) stimulated NCI-H292 human airway epithelial cell MUC5AC gene expression and mucus production with IC50 value of 1.4 µM.

Anti-Mouse CCR2 Antibody (C2Mab-6) is a monoclonal antibody targeting mouse CC chemokine receptor type 2 (mCCR2), with a K_D value of 0.18-1.6 nM. Anti-Mouse CCR2 Antibody (C2Mab-6) exhibits high binding affinity to cells expressing mCCR2 and shows no reactivity to parental CHO-K1 cells. Anti-Mouse CCR2 Antibody (C2Mab-6) recognizes the amino acid region spanning positions 1-19 of mCCR2, and its key binding epitope includes Asp3, Asn4, Met6, Pro8, Gln9 and Phe10. Anti-Mouse CCR2 Antibody (C2Mab-6) can be used in leukemia-related research.